Drugs / OS2966
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04608812 | Mar 2021 → Feb 2023 | anaplastic astrocytoma, glioblastoma | OncoSynergy, Inc. | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-05-03 | OncoSynergy, Inc. | Regulatory FDA Grants Third Orphan Drug Designation for OS2966 oncosynergy.com ↗
Based on that data from CHLA, the FDA granted OncoSynergy Inc. orphan drug designation for the compound, OS2966, a first-in-class monoclonal antibody that targets a protein called integrin beta-1. |
| 2019-04-26 | OncoSynergy, Inc. | Regulatory FDA Acceptance of IND Application for Phase I Trial of OS2966 in Patients with Recurrent Glioblastoma oncosynergy.com ↗
OncoSynergy, Inc., a patient-focused oncology company committed to advancing therapeutics to address dire unmet medical needs, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for OS2966, a first-in-class therapeutic targeting CD29. |
| 2019-02-25 | OncoSynergy, Inc. | Regulatory OncoSynergy Announces Submission of IND Application for OS2966 in the Treatment of Glioblastoma oncosynergy.com ↗ |
| 2015-03-17 | OncoSynergy, Inc. | Regulatory FDA Grants Second Orphan Drug Designation for OS2966 oncosynergy.com ↗
OncoSynergy announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for OS2966 in the treatment of ovarian cancer. |
| 2014-08-12 | OncoSynergy, Inc. | Regulatory Orphan Drug Designation Obtained for OS2966 oncosynergy.com ↗ |
All press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-05-03 | OncoSynergy, Inc. | FDA Grants Third Orphan Drug Designation for OS2966 oncosynergy.com ↗ |
| 2021-04-16 | OncoSynergy, Inc. | OncoSynergy Announces First Patient Treated in First-in-Human Clinical Trial of OS2966 in Recurrent Glioblastoma oncosynergy.com ↗ |
| 2019-04-26 | OncoSynergy, Inc. | FDA Acceptance of IND Application for Phase I Trial of OS2966 in Patients with Recurrent Glioblastoma oncosynergy.com ↗ |
| 2019-02-25 | OncoSynergy, Inc. | OncoSynergy Announces Submission of IND Application for OS2966 in the Treatment of Glioblastoma oncosynergy.com ↗ |
| 2015-03-17 | OncoSynergy, Inc. | FDA Grants Second Orphan Drug Designation for OS2966 oncosynergy.com ↗ |
| 2014-08-12 | OncoSynergy, Inc. | Orphan Drug Designation Obtained for OS2966 oncosynergy.com ↗ |
| 2013-12-17 | OncoSynergy, Inc. | OncoSynergy and CMC Biologics Enter into Agreement for OS2966 Drug Program oncosynergy.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OS2966 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04608812 ↗ |
| Modality | Monoclonal antibody | “OS2966 is an anti-CD29 (Beta1 Integrin) monoclonal antibody (mAb)” NCT04608812 ↗ |
| Route | Other | “participants will receive a single intratumoral infusion of OS2966 directly to the contrast-enhancing bulk tumor by CED” NCT04608812 ↗ |